2.7000 +0.06 (2.27%)
After hours: 5:21PM EST
Previous Close | 2.9100 |
Open | 2.9200 |
Bid | 2.6300 x 900 |
Ask | 2.6400 x 900 |
Day's Range | 2.5000 - 2.9899 |
52 Week Range | 1.5500 - 8.8500 |
Volume | 514,055 |
Avg. Volume | 855,521 |
Market Cap | 49.172M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
NEW YORK, NY / ACCESSWIRE / February 24, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Cleveland BioLabs, Inc. (NASDAQ:CBLI) relating to the creation of a combined company between the Company and Cytocom, Inc.
Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence.